Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
09/27/1995 | EP0673648A1 Compositions comprising amphotoic salts of alpha-hydroxy acids and glycerol monocaprylate |
09/27/1995 | EP0673366A1 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
09/27/1995 | EP0673255A1 Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof |
09/27/1995 | EP0673241A1 A free radical quenching liposomal composition |
09/27/1995 | EP0462189B1 Combination therapy for treatment of estrogen sensitive diseases |
09/27/1995 | EP0348490B1 Treatment of type 2 diabetes mellitus |
09/27/1995 | EP0311677B1 Cough/cold mixtures comprising non-sedating antihistamine drugs |
09/27/1995 | CN1108934A Pharmaceutical compositions and usages |
09/26/1995 | US5453446 Use of rasagiline or salts thereof |
09/26/1995 | US5453428 Method and composition for the treatment of apathy-amotivation syndrome |
09/23/1995 | CA2142940A1 Method and composition having enhanced alpha-hydroxy skin permeation and retention |
09/21/1995 | WO1995024921A1 A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction |
09/21/1995 | WO1995024917A1 Skin treatment composition |
09/21/1995 | WO1995024910A1 Immunotherapy of cancer with allogeneic lymphocytes |
09/21/1995 | WO1995024896A2 Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne |
09/21/1995 | WO1995024888A1 Methods for phototherapeutic treatment of proliferative skin diseases |
09/21/1995 | WO1995021612A3 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
09/21/1995 | CA2185675A1 Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne |
09/21/1995 | CA2185440A1 Methods for phototherapeutic treatment of proliferative skin diseases |
09/21/1995 | CA2184352A1 Immunotherapy of cancer with allogeneic lymphocytes |
09/21/1995 | CA2181162A1 Skin treatment composition |
09/20/1995 | EP0672192A1 Method for inhibition of viral morphogenesis |
09/20/1995 | EP0672145A1 Interleukin-3 (il-3) multiple mutation polypeptides |
09/20/1995 | EP0671952A1 Method for nonspecific cellular immune stimulation |
09/20/1995 | EP0671936A1 TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
09/20/1995 | EP0671910A1 Glaucoma treatment |
09/20/1995 | EP0671909A1 Syndecan stimulation of cellular differentiation |
09/20/1995 | EP0671908A1 Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers |
09/20/1995 | EP0458965B1 Process for the preparation of vinyl ethers |
09/20/1995 | CN1108655A 1,3-oxathiolane nucleoside analogues |
09/20/1995 | CN1108654A Methods of treating menstrual symtoms and compositions therefore |
09/20/1995 | CN1108537A Housewife dermatitis treatment |
09/20/1995 | CN1029770C Controlled release bases for pharmaceuticals |
09/19/1995 | US5451569 No micelles or liposomes |
09/19/1995 | US5451518 Purified human ceramide-activated protein kinase |
09/14/1995 | WO1995024414A1 Fibroblast growth factor-10 |
09/14/1995 | WO1995024379A1 Benzamide analogs, useful as parp (adp-ribosyltransferase, adprt) dna repair enzyme inhibitors |
09/14/1995 | WO1995024221A1 Bioactive and/or targeted dendrimer conjugates |
09/14/1995 | WO1995024211A1 Use of fibroblast growth factors to stimulate bone growth |
09/14/1995 | WO1995024194A1 Treatment of obsessive-compulsive disorders with 5-ht2 antagonists |
09/14/1995 | CA2183961A1 Fibroblast growth factor-10 |
09/13/1995 | EP0671175A2 Sustained release compositions for treating periodontal disease |
09/13/1995 | EP0671171A1 Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events |
09/13/1995 | EP0671168A1 Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
09/13/1995 | EP0671167A1 Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
09/13/1995 | EP0671166A2 Nutrient-supplying preparation |
09/13/1995 | EP0671162A2 Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
09/13/1995 | EP0670898A1 Interleukin-3 (il-3) mutant polypeptides |
09/13/1995 | EP0563094B1 Pharmaceutical compositions |
09/13/1995 | CN1108104A Pharmaceutical moenomycin and derivative of same medicament containing moenomycin or derivative of same |
09/13/1995 | CN1108089A Cosmetic or skin using composition of emulsion of oil covered with water formed with oil drops and covered with liquid |
09/12/1995 | US5449663 L-Glucose |
09/12/1995 | US5449522 Antitumor |
09/12/1995 | US5449520 Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level |
09/12/1995 | US5449355 Retrograde tissue splitter and method |
09/12/1995 | CA1336963C Method for inhibiting myocardial cell necrosis and preserving heart function during myocardial ischemia and/or reperfusion |
09/12/1995 | CA1336953C Method of preventing or reducing adverse reactions to protamine using a thromboxane a _receptor antagonist |
09/08/1995 | WO1995023610A1 Pharmaceutical composition containing thymoctonan and azt |
09/08/1995 | WO1995023605A1 Method for treating and inhibiting gastric and duodenal ulcers |
09/08/1995 | WO1995023602A1 Antitussive composition containing an antitussive and benzydamine |
09/08/1995 | CA2183329A1 Method for treating and inhibiting gastric and duodenal ulcers |
09/08/1995 | CA2160248A1 Pharmaceutical composition containing thymoctonan and azt |
09/06/1995 | EP0669931A1 17-alpha-acyl steroids which inhibit 5-alpha-reductase |
09/06/1995 | EP0669830A1 Substituted dipeptide analogs promote release of growth hormone |
09/05/1995 | US5447940 Reinforced collagen matrix, dispersed antibiotic, analgesic, antiinflammatory, antiseptic |
09/05/1995 | US5447912 Injecting the neuropeptides VIP and PHM and an adrenergic blocking agent |
09/05/1995 | CA1336887C Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
09/02/1995 | CA2143604A1 Fatty acid derivatives |
08/30/1995 | EP0669129A2 Expandable release controlled medicaments |
08/30/1995 | EP0668933A1 Use of methioninase as an antitumor agent in anti-methionine chemotherapy |
08/30/1995 | EP0668913A1 Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
08/30/1995 | EP0668854A1 Use of n-arylmethylene, ethylenediaminetriacetates n-arylmethylene iminodiacentates or n, n'-diarylmethylene ethylenediaminacetates for use in combatting oxidative stress |
08/30/1995 | EP0668782A1 Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer |
08/30/1995 | EP0668760A1 Use of a cell membrane permeant calcium buffer for reducing injury of mammalian cells in vivo |
08/30/1995 | EP0668727A1 Method for enhancing bioavailability of beta-carotene. |
08/30/1995 | EP0485577B1 Immunostimulant drug based on polar glycopeptidolipids of mycobacterium chelonae |
08/30/1995 | CN1107366A Foaming mixture of alkalis salt or lysine salt with acid unresolvable or difficult resolving active material |
08/30/1995 | CN1107365A A novel physiologically active substance |
08/30/1995 | CN1107364A Pharmaceutical combination |
08/29/1995 | US5446091 Collagen-polymer conjugates containing an ether linkage |
08/29/1995 | US5446028 Peroxide and an antibiotic selected from lincomycin family of antibiotics comprises clindamycin or salt or ester |
08/29/1995 | CA1336825C Use and agent for reducing the side effects of tnf |
08/29/1995 | CA1336810C Synergistic interplay of lymphokines and double stranded rnas |
08/24/1995 | WO1995022619A1 B7-1-specific ligands, and their use for the induction of t cell anergy |
08/24/1995 | WO1995022557A1 Novel opioid peptides for the treatment of pain and use thereof |
08/24/1995 | WO1995022350A1 Composition and method for preventing and treating inflammation with immunoglobulin a |
08/24/1995 | WO1995022345A1 A method and agents for control and management of labor during pregnancy |
08/24/1995 | WO1995022340A1 Methods for altering fertility |
08/24/1995 | DE19505287A1 Zusammensetzung und Verfahren zur Prävention und Behandlung von Entzündungen mit Immunglobulin A A composition and method for the prevention and treatment of inflammation with immunoglobulin A |
08/24/1995 | CA2183680A1 B7-1-specific ligands, and their use for the induction of t cell anergy |
08/24/1995 | CA2183566A1 Composition and method for preventing and treating inflammation with immunoglobulin a |
08/24/1995 | CA2181367A1 Novel opioid peptides for the treatment of pain and use thereof |
08/23/1995 | EP0668279A2 6-Azaindole thromboxane synthase inhibitors |
08/23/1995 | EP0667959A1 METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE $g(b)-AMYLOID PEPTIDE |
08/23/1995 | EP0667911A1 Stably-transformed mammalian cells expressing a regulated, inflammatory cyclooxygenase |
08/23/1995 | EP0667780A1 Purified ceramide-activated protein kinase, assay for identifying agents which act on same, and methods of using said agents |
08/23/1995 | EP0667771A1 Antitumour compositions containing taxane derivatives |
08/23/1995 | EP0667769A1 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
08/22/1995 | US5444069 Imidazo-pyridine angiotensin II antagonists used to treat memory loss |
08/22/1995 | US5443962 Methods of identifying inhibitors of cdc25 phosphatase |